Also known as: Thymic Factor, Thymalin Peptide, Thymus Extract Peptide
Immune restoration and anti-aging via thymic function support
Amount
5-10 mg
Frequency
Once daily
Duration
3-10 day course, repeated every 1-6 months
Route
IMSchedule
Once daily
Timing
Morning administration preferred; no specific fasting requirement
โ Rotate injection sites
Duration
3-10 day course, repeated every 1-6 months
Repeatable
Yes
Course-based protocol with rest periods
Diluent: Sterile water
Use within: Use immediately after reconstitution
Storage: Store lyophilized thymalin at 2-8 degrees Celsius (refrigerated) protected from light. Do not freeze. Shelf life is typically 2-3 years for the lyophilized product when stored properly. Reconstituted solution should be used immediately; do not store reconstituted thymalin.
CBC with differential
When: Baseline
Why: Baseline immune cell counts
Lymphocyte subset panel (CD3, CD4, CD8, NK cells)
When: Baseline
Why: Thymalin specifically targets T-cell function
CD4/CD8 ratio
When: Baseline
Why: Key immune balance indicator; thymalin aims to normalize this
Immunoglobulin levels (IgG, IgA, IgM)
When: Baseline
Why: Humoral immunity baseline
CMP
When: Baseline
Why: General organ function
Lymphocyte subset panel
When: 2-4 weeks after completing course
Why: Assess immune reconstitution response
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Thymalin is a polypeptide complex originally isolated from the thymus gland of calves and developed as a pharmaceutical preparation by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia during the 1970s and 1980s. It represents one of the foundational products of the Russian bioregulatory peptide therapy paradigm, a research tradition that proposes short peptides can regulate gene expression and restore age-related functional decline in specific organ systems.
The thymus gland plays a central role in adaptive immunity by serving as the site where T-cell precursors from the bone marrow undergo maturation, selection, and differentiation into functional T lymphocytes. The thymus is one of the first organs to undergo age-related involution, beginning around puberty and progressively shrinking throughout adulthood. By age 60-70, the thymus has lost the majority of its functional tissue, replaced by adipose tissue. This thymic involution is directly correlated with the decline in naive T-cell output, weakened immune surveillance, increased susceptibility to infections, and higher cancer incidence in the elderly. Thymalin was developed to counteract this immunological aging by providing thymic peptide factors exogenously.
Unlike most peptides covered on this site, Thymalin is not a single defined peptide with a known amino acid sequence. It is a polypeptide complex, a mixture of low-molecular-weight peptides extracted from the thymus gland through a standardized extraction and purification process. The preparation contains multiple bioactive peptide fractions, with the most studied active components being the dipeptides glutamyl-tryptophan (EW, also known as thymogen) and lysyl-glutamyl (KE, also known as vilon).
The extraction process involves acid hydrolysis of bovine thymus tissue followed by ultrafiltration to isolate peptides below 10 kDa. The resulting preparation is lyophilized into a sterile powder for reconstitution and injection. Each batch contains a reproducible profile of thymic peptide factors, though the exact composition is more complex than a single synthetic peptide.
Thymogen (EW dipeptide) has been separately developed as a synthetic peptide drug and is also approved in Russia for immune modulation. The identification of these active dipeptide components has supported the concept that the biological activity of thymalin can be attributed to specific short peptide sequences rather than the entire extract.
Thymalin exerts its biological effects through multiple interconnected pathways centered on immune system modulation and restoration of thymic function.
The primary mechanism involves supporting and restoring the thymic microenvironment necessary for T-cell development. Thymalin peptides interact with thymic epithelial cells, promoting the expression of factors required for thymocyte selection and maturation. This includes upregulation of major histocompatibility complex molecules on thymic epithelial cells, support for positive and negative selection processes, enhanced output of mature naive T cells, and restoration of the CD4/CD8 T-cell ratio toward youthful values.
Clinical studies in elderly subjects have demonstrated that thymalin administration can restore multiple immune parameters that decline with age. These include normalization of total T-lymphocyte counts, improvement of natural killer cell activity, modulation of cytokine profiles toward balanced Th1/Th2 responses, and enhancement of phagocytic activity of neutrophils and macrophages. The effect appears to be immunomodulatory rather than purely immunostimulatory, meaning that thymalin tends to normalize aberrant immune parameters rather than simply boosting all immune responses indiscriminately.
Research by Khavinson and colleagues has demonstrated an important functional connection between the thymus and the pineal gland, termed the pineal-thymic axis. Thymalin administration in aged animals and humans has been shown to influence pineal function, specifically modulating melatonin secretion patterns. Conversely, the pineal peptide epitalon has been shown to influence thymic function. This bidirectional relationship suggests that thymalin acts not only directly on the immune system but also through neuroendocrine pathways that integrate immune function with circadian rhythms and hormonal regulation.
The bioregulatory peptide theory advanced by Khavinson proposes that short peptides can interact directly with DNA through specific binding to gene promoter regions, influencing transcription. Studies using the active dipeptide components of thymalin (EW and KE) have demonstrated binding to specific DNA sequences and modulation of gene expression in cell culture models. While this mechanism remains somewhat controversial and is not universally accepted by the broader scientific community, it provides a theoretical framework for how small peptides might produce systemic effects beyond simple receptor-ligand interactions.
Thymalin was first developed in the 1970s as part of a Soviet-era research program to develop bioregulatory peptides for military and civilian medical applications. It received regulatory approval in Russia for clinical use in immune deficiency states, and it has been used in Russian clinical medicine for several decades. The approved indications in Russia include immune restoration after infections, immunodeficiency states, adjunctive treatment during chemotherapy and radiation therapy, and age-related immune decline.
Outside of Russia and the former Soviet states, thymalin has not received regulatory approval. It is not approved by the FDA, EMA, or other major Western regulatory agencies. The evidence base, while substantial within Russian-language medical literature, has limited representation in Western peer-reviewed journals, which creates a significant gap in international recognition of the compound.
The most remarkable published findings for thymalin come from long-term human studies conducted by Khavinson's research group examining mortality outcomes in elderly populations. In a study published in 2003, elderly subjects who received courses of thymalin and epitalon showed a 2.0-fold decrease in mortality over a 6-year follow-up period compared to control subjects. A subsequent 15-year follow-up study reported similar mortality reductions in treated groups.
These longevity findings, while striking, must be interpreted with significant caveats. The studies were not randomized double-blind placebo-controlled trials by Western standards. They were conducted primarily by the developers of the compound, raising concerns about potential bias. The mechanism by which immune restoration would produce such dramatic mortality benefits is not fully elucidated. Independent replication by researchers outside the Khavinson group has not been published.
Despite these limitations, the consistent direction of findings across multiple studies and the biological plausibility of the immune restoration hypothesis have generated interest in thymalin within the gerontology and longevity research communities.
The combination of thymalin (thymic peptide) and epitalon (pineal peptide) represents the most studied bioregulatory peptide combination. The rationale is based on the pineal-thymic axis: simultaneously restoring both thymic immune function and pineal melatonin production may produce synergistic anti-aging effects. The longevity studies by Khavinson used this combination, reporting mortality reductions greater than either peptide alone.
Thymosin alpha-1 is a well-characterized 28-amino-acid peptide that also originates from thymic tissue and has been approved in multiple countries for hepatitis B treatment. While both target immune restoration, they work through partially different mechanisms, and their combination has been theorized to provide more comprehensive immune support.
Thymalin occupies a unique position in peptide research. It is an approved pharmaceutical product in Russia with decades of clinical use, yet it remains largely unknown in Western medicine. The research paradigm from which it emerged, bioregulatory peptide therapy, is an active field in Russian gerontology but has had limited penetration into international research circles. The core claims, that short peptides can restore organ function and extend lifespan, are extraordinary and require extraordinary evidence, which remains incomplete by the standards of evidence-based medicine as practiced internationally. Current research efforts are focused on further characterizing the active peptide components, understanding the molecular mechanisms of gene regulation by short peptides, and attempting to conduct studies that meet international standards for clinical evidence.
Peptides of pineal gland and thymus prolong human life, published in Neuro Endocrinology Letters (Khavinson VK and Morozov VG, 2003; PMID: 14523363):
Comprehensive report on long-term human study of thymalin and epitalon in elderly subjects, demonstrating 2.0-fold mortality decrease over 6-year follow-up compared to controls.
Geroprotective effect of thymalin and epitalon peptide bioregulators, published in Advances in Gerontology (Khavinson VK and Morozov VG, 2002; PMID: 12577695):
Report on the geroprotective effects of thymalin and epitalon in elderly subjects with 6-8 year follow-up demonstrating mortality reduction and immune parameter improvement.
Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells, published in Bulletin of Experimental Biology and Medicine (Khavinson VK et al., 2020; PMID: 33237528):
Study demonstrating that thymalin-derived peptides promote differentiation of hematopoietic stem cells toward thymocyte lineage, providing mechanistic support for thymalin's immune restoration effects.
Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19, published in Stem Cell Reviews and Reports (Khavinson VK et al., 2021; PMID: 33575961):
Review proposing thymus peptides including thymalin for COVID-19 therapy based on their immunomodulatory properties and potential to restore T-cell function compromised by SARS-CoV-2.
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
Based on 45+ community reports
View community protocolsResearch-grade suppliers verified by our scoring methodology.
Epitalon: Telomerase-activating anti-aging tetrapeptide. Covers telomere elongation, pineal gland modulation, Khavinson research, and dosing data.
Glutathione: The body's master antioxidant tripeptide. Covers redox cycling, detoxification, immune support, IV vs oral bioavailability, and dosing.
Thymosin Alpha-1: Immunomodulator approved in 35+ countries. Covers T-cell and dendritic cell activation, hepatitis B trials, Zadaxin dosing, and safety.
Afamelanotide (Scenesse): FDA-approved MC1R agonist for erythropoietic protoporphyria. Subcutaneous implant increases pain-free sun exposure via melanogenesis.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin). Evidence quality assessment for each approach.
Comprehensive research review of immune-modulating peptides including thymosin alpha-1, KPV, LL-37, thymalin, VIP, and glutathione. Clinical evidence, mechanisms of immune regulation, and implications for autoimmune and inflammatory conditions.
Guide to Khavinson bioregulator peptides for aging including Epitalon, Vilon, Thymalin, and Pinealon with mechanisms, clinical data, and evidence review.
Comprehensive guide to thymic peptides including Thymosin Alpha-1, Thymalin, and Vilon โ mechanisms, thymic involution, and immune restoration research.
Related content you may find interesting